FDA Approves Orca-T for GVHD Prevention in Stem Cell Transplants

The U.S. Food and Drug Administration (FDA) approved Orca-T on January 24, 2024, marking a significant advancement in the treatment of blood cancers. Orca-T is an allogeneic regulatory T cell-based immunotherapy designed to prevent graft-versus-host disease (GVHD), a serious and potentially life-threatening complication following hematopoietic stem cell transplantation (HSCT).

This approval specifically targets patients with hematologic malignancies, such as leukemia and lymphoma, who are undergoing HSCT. GVHD occurs when the donor's immune cells (graft) attack the recipient's body (host). Orca-T works by delivering a specific population of T cells that are engineered to suppress the immune response, thereby mitigating the risk of the donor cells attacking the patient's tissues.

The development and approval of Orca-T represent a collaborative effort, with the therapy originating from the laboratory of Dr. Irfan Qureshi at the University of California, San Francisco (UCSF). The product is manufactured by Oricula Therapeutics, a company founded to advance this innovative cell therapy. Clinical trials demonstrated Orca-T's efficacy in reducing the incidence and severity of both acute and chronic GVHD, while preserving the graft-versus-leukemia effect, which is crucial for eliminating residual cancer cells.

This approval is a critical step forward, offering a new therapeutic option for transplant centers and patients facing the challenges of HSCT. By proactively preventing GVHD, Orca-T aims to improve transplant outcomes, reduce the need for broad immunosuppression, and enhance the overall quality of life for individuals battling blood cancers. The therapy is administered alongside hematopoietic stem and progenitor cells (HSPCs) and T cells, forming a comprehensive treatment regimen.